drugset / Trial / NCT05987696
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Phase 1
Completed
2 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Hangzhou Qihan Biotech Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of iPSC NK cells in patients with relapsed/refractory AML or AML Minimal Residual Disease (MRD).
Timeline
- Start
- 2023-07-31
- Primary completion
- 2025-01-17
- Completion
- 2025-01-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD33 CAR-NK cell | Cell therapy | — | — |
| Subject | CD33/CLL1 dual CAR-NK cell | Cell therapy | — | — |
| Subject | super NK cell | Cell therapy | — | — |
| Background | Cyclophosphamid | Unknown | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |